Agents to treat BRAF-mutant lung cancer

BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez, Jean G Bustamante, Otterson, Gregory A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419923/
https://www.ncbi.nlm.nih.gov/pubmed/30899313
http://dx.doi.org/10.7573/dic.212566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419923/
https://www.ncbi.nlm.nih.gov/pubmed/30899313
http://dx.doi.org/10.7573/dic.212566

Ejemplares similares